PR95238

SINGAPORE,March30,2022/PRNewswire=KYODO JBN/--

GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK) receives the

"Best Contract Development and Manufacturing Organization Award" on the Asia

Pacific Bioprocessing Excellence Awards 2022. This marks the third consecutive

year of GenScript bagging the same award in Asia Pacific region. The award also

follows GenScript's recognition at the Korea Bioprocessing Excellence Awards in

2021 for the "Best Contract Development and Manufacturing Organization Award".

"We are honored to be recognized once again by our customers and industry peers

as the leading CDMO service partner to the biopharmaceutical industry. This

award is a solid testament to our continuous effort and dedication to maintain

our global position as the top solutions and service provider to accelerate

drug development, next generation vaccines and therapies", said Dr. Kun Yin,

Senior Director of Business Development, GenScript ProBio Asia Pacific

division. "We will continue to strive for excellence by leveraging our

technology platforms and expertise to provide the best solution to our

customers and partners."

Asia Pacific Bioprocessing Excellence Awards 2022 recognizes exceptional

bioprocessing experts, organizations and technologies that facilitate

biomanufacturing excellence at enhanced speed, reduced cost, and superior

quality. The panel of expert judges include Key Opinion Leaders with more than

20 years of experience, Process Development Vice Presidents and Directors,

Heads of Manufacturing and Bioprocessing from all the key players in Asia and

globally. GenScript emerges as the winner for the best CDMO award among the

industry peers in Asia Pacific region.

In January 2022, GenScript ProBio, which is the CDMO division of GenScript

broke ground for the construction of its newest 34,000 square meter plasmid and

viral vector manufacturing facility. The facility will be state-of-the-art,

utilizing the latest technology and equipment in viral vector and plasmid

manufacturing to scale up its production capacity and deliver end-to-end cell

and gene therapy CDMO services. Many projects for COVID-19 mRNA vaccine from

China have been carried out in GenScript ProBio's plasmid manufacturing

facility. Besides supporting many mRNA vaccine enterprises in China to obtain

clinical approvals by NMPA, GenScript ProBio also helped mRNA vaccine projects

from South Korea and the United States companies to obtain clinical approvals

in South Korea and Japan.

"Cell and gene therapy is the forefront of innovation to treat severe and rare

diseases, in the coming years, GenScript will focus on putting our dedication

and investment to partner with scientists and develop drugs and therapies to

improve human lives." said Dr. Kun Yin during the award ceremony.

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is the world's leading

technology and service provider of life science R&D and manufacture. Built upon

its solid gene synthesis technology, GenScript Biotech is divided into four

major platforms including the life science service and product platform, the

biologics contract development and manufacturing organization (CDMO) platform,

the global cell therapy platform and the industrial synthesis biological

product platform.

GenScript Biotech was founded in New Jersey, US in 2002 and listed on the Hong

Kong Stock Exchange in 2015. GenScript Biotech's business operations span over

100 countries and regions worldwide with legal entities located in the US,

Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands and

Ireland. GenScript Biotech provides premium, convenient and reliable services

and products for over 100,000 customers.

As of December 31, 2021, GenScript Biotech had more than 5,200 employees

globally, over 40% of whom hold master's and/or Ph.D. degrees. In addition,

GenScript Biotech owns a number of intellectual property rights, including over

180 patents, over 670 pending patent applications and great numbers of trade

secrets.

Driven by the corporate mission of "making people and nature healthier through

biotechnology", GenScript Biotech strives to become the most trustworthy

biotech company in the world. As of December 31, 2021, GenScript Biotech's

services and products have been cited by 65,600 peer-reviewed journal articles

worldwide.

For more information, please visit GenScript Biotech's official website

https://www.genscript.com.

About GenScript ProBio – Biologics CDMO

GenScript ProBio is the subsidiary of GenScript Biotech Corporation,

proactively providing end-to-end CDMO service from drug discovery to

commercialization with proactive strategies, professional solutions and

efficient processes in gene and cell therapy (GCT), vaccine, biologics

discovery and antibody protein drug to accelerate drug development for

customers.

GenScript ProBio's total gene and cell therapy solution covers CMC of plasmid

and virus for IND filing as well as clinical manufacturing and commercial

manufacturing. GenScript ProBio's innovative solutions for biologics discovery

and development include therapeutic antibody discovery, antibody engineering

and antibody characterization. GMP capacity which meets FDA, EMA and NMPA

regulatory requirements.

Toward the mission of "Innovation through Collaboration", GenScript ProBio is

committed to helping customers shorten the timeline for the development of

biological drugs from discovery to commercialization, significantly lowering

R&D costs and building a healthier future.

Source: Genscript

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=418116

   Link: http://asianetnews.net/view-attachment?attach-id=418119

   Caption: Dr. Kun Yin, Senior Director of Business Development, GenScript ProBio Asia

Pacific division receiving the best CDMO award on the virtual ceremony.